Anabolic steroid side effects are real, documented and in several cases serious. They are also manageable — with the right compounds, doses, monitoring protocols and support. This guide covers every major side effect category with the underlying mechanism, severity by compound, which effects are reversible versus permanent, and what you can do practically to reduce risk. The goal is not to discourage use but to ensure informed decisions based on accurate information rather than exaggeration in either direction.
For the foundational science before reading this: What Are Anabolic Steroids? — and for practical cycle planning with harm reduction built in: Steroid Cycle Planning: The 2026 Evidence Guide.
Cardiovascular Side Effects
Cardiovascular impact is the most clinically significant long-term risk of AAS use — and the area where the evidence is strongest. A 2025 review in Current Opinion in Cardiology confirmed that AAS use is associated with elevated blood pressure, adverse lipid profiles, accelerated atherosclerosis, subclinical cardiomyopathy and increased risk of myocardial infarction and sudden cardiac death.
Left Ventricular Hypertrophy (LVH)
The most documented structural cardiac consequence of AAS use. Androgen receptor activation in cardiomyocytes directly stimulates myocardial protein synthesis — the same mechanism that builds skeletal muscle also hypertrophies cardiac muscle. LVH develops silently — no symptoms until advanced. Echocardiography is the only detection method. A 2004 study confirmed that concentric LVH persists in ex-AAS users several years after cessation — these cardiac changes are not fully reversible.
Lipid Dysregulation
All AAS reduce HDL cholesterol and increase LDL cholesterol to varying degrees. Oral 17-alpha alkylated steroids produce the most severe lipid dysregulation — particularly stanozolol (Winstrol) and oxymetholone (Anadrol), which can reduce HDL by 50%+ within weeks. The cardiovascular risk from sustained HDL suppression is real and cumulative across multiple cycles.
Blood Pressure
AAS elevate blood pressure through multiple mechanisms: water and sodium retention from aromatising compounds, increased RBC production raising blood viscosity (particularly with Deca and EQ), direct effects on vascular tone, and haematocrit elevation from erythropoietic compounds. Sustained blood pressure above 140/90 during a cycle requires immediate intervention.
Haematocrit Elevation
AAS stimulate erythropoiesis — red blood cell production. Elevated haematocrit increases blood viscosity and thrombotic risk. Above 52% haematocrit, the risk of clotting events increases substantially. This is particularly pronounced with Deca, EQ and high-dose testosterone.
| Cardiovascular Risk | Compounds Most Associated | Monitoring | Management |
|---|---|---|---|
| LVH | All AAS — cumulative with long-term use | Annual echo for 3+ year users | Shorter cycles, adequate off-time |
| HDL suppression | Stanozolol, Anadrol — worst; Anavar, Primo — mildest | Lipid panel pre/mid/post cycle | Cardiovascular training, fish oil, adequate off-time |
| Blood pressure elevation | Testosterone, Deca, Anadrol — worst; Anavar, Primo — mildest | Daily home BP monitoring | Reduce dose, manage water retention, consider Amlodipine if persistent |
| Haematocrit elevation | Deca, EQ, Testosterone — significant | CBC mid-cycle and post-cycle | Therapeutic phlebotomy if above 52%, avoid high doses |
Hormonal Suppression and HPG Axis
Every anabolic steroid — without exception — suppresses natural testosterone production by shutting down the hypothalamic-pituitary-gonadal (HPG) axis. This is not a risk that affects some users — it is a universal pharmacological consequence.
Mechanism
The hypothalamus detects high androgen levels and reduces GnRH output. The pituitary responds by reducing LH and FSH to near zero. Without LH stimulation, testicular Leydig cells stop producing testosterone. Complete shutdown typically occurs within 2–4 weeks of starting a cycle regardless of compound.
Consequences of Suppression Without PCT
- Testicular atrophy: without LH stimulation, testes reduce in size — visible within weeks of cycle start
- Azoospermia: FSH suppression reduces or eliminates sperm production — fertility impact during and after cycle
- Post-cycle hypogonadism: without PCT, natural testosterone recovery takes 3–12 months with severe symptoms throughout
- Permanent hypogonadism risk: in a subset of long-term users without PCT, the HPG axis loses responsiveness — requiring ongoing TRT
Nolvadex and Clomid — and increasingly Enclomiphene — are used in PCT to restart the HPG axis. For the complete protocol: PCT — Post Cycle Therapy: The Complete Guide and Will Steroids Shut Down Testosterone?
Prolactin — 19-Nor Compounds
Nandrolone (Deca) and Trenbolone are 19-nor compounds that additionally elevate prolactin through progestin receptor activity. Elevated prolactin causes sexual dysfunction — reduced libido and erectile dysfunction — that does not resolve with SERMs alone. Cabergoline is required to manage prolactin on 19-nor cycles.
Estrogenic Side Effects
Aromatising AAS (testosterone, nandrolone, boldenone, methandrostenolone) convert to estrogen via the aromatase enzyme. Elevated estrogen produces specific side effects distinct from androgenic effects:
Gynecomastia
Breast tissue development in males from estrogen receptor activation in mammary glandular tissue. Early signs: nipple sensitivity, itching, puffy nipples. If caught early and compound stopped or AI added — usually reversible. If tissue hardens and glandular tissue develops — surgical intervention (mastectomy) may be required. Early identification and response is critical.
Water Retention
Estrogen causes sodium and water retention — the "wet" gains associated with testosterone and Dianabol cycles. Mild water retention is cosmetic. Significant water retention contributes to blood pressure elevation. Managed with aromatase inhibitors — but see the note on E2 management below.
Estrogen Management
Have Arimidex or Aromasin available but use reactively — not prophylactically. Excessive AI use crashes E2 below optimal levels, producing its own set of problems: joint pain, low libido, depression, cognitive fog. The goal is optimal estrogen, not minimum estrogen.
Androgenic Side Effects
Androgenic effects are driven by DHT conversion and direct androgenic receptor activation in skin, hair follicles, sebaceous glands and the prostate. The degree of androgenic side effects depends heavily on the compound's androgenic rating and individual genetic sensitivity.
Acne
The most common androgenic side effect. DHT stimulates sebaceous gland activity — increased sebum production creates the environment for acne formation. Back, chest and shoulder acne (body acne) is characteristic of AAS-related acne. Severity varies dramatically between individuals — some users at 400 mg/week testosterone experience no acne; others develop severe acne at 200 mg/week. Genetic predisposition is the primary determinant.
Management: Accutane (Isotretinoin) is the most effective pharmaceutical treatment for severe AAS-related acne.
Male Pattern Baldness Acceleration
AAS accelerate androgenetic alopecia (male pattern baldness) in genetically predisposed individuals — they do not cause baldness in those without genetic predisposition. DHT binds to receptors in hair follicles on the scalp, miniaturising them over time. 5-alpha reductase inhibitors like Finasteride reduce DHT conversion — effective for testosterone-based cycles but ineffective for compounds that are already DHT derivatives (Masteron, Winstrol) or do not convert via 5α-reductase (Trenbolone, Nandrolone).
Compounds least likely to accelerate hair loss: Deca, Anavar, Primobolan. Most aggressive: Trenbolone, Winstrol, Masteron, high-dose testosterone.
Prostate Effects
DHT stimulates prostate growth. Prolonged AAS use with high androgenic load can contribute to benign prostatic hyperplasia (BPH) symptoms — urinary flow reduction, frequency. PSA monitoring is recommended for users over 40. Finasteride reduces DHT-mediated prostate stimulation alongside its hair protection effect.
| Androgenic Side Effect | Most Androgenic Compounds | Least Androgenic | Management |
|---|---|---|---|
| Acne | Testosterone, Trenbolone, Winstrol | Deca, Anavar, Primobolan | Accutane for severe cases, benzoyl peroxide topically |
| Hair loss acceleration | Winstrol, Masteron, Trenbolone | Deca, Anavar, Primobolan | Finasteride (testosterone only), Minoxidil |
| Prostate stimulation | Testosterone (DHT), Masteron | Deca, Primobolan | Finasteride, PSA monitoring, avoid high androgenic dose |
Liver (Hepatic) Side Effects
Hepatotoxicity is primarily associated with oral 17-alpha alkylated (17-aa) steroids — the chemical modification that allows oral bioavailability simultaneously damages liver function. Injectable steroids bypass first-pass liver metabolism and are not 17-aa — their hepatic impact is significantly lower at standard doses.
Mechanism of 17-aa Hepatotoxicity
C17-alpha alkylation makes the compound resistant to liver breakdown — the same modification that allows the oral to reach systemic circulation also produces reactive oxygen species, impairs bile transport, and disrupts mitochondrial function in hepatocytes. The spectrum of hepatic injury ranges from mild ALT/AST elevation (common) to cholestasis, peliosis hepatis and in severe long-term cases hepatocellular carcinoma.
Hepatotoxicity by Compound
| Compound | Hepatotoxicity Level | Max Duration |
|---|---|---|
| Superdrol (Methyldrostanolone) | Very High | 3–4 weeks maximum |
| Oxymetholone (Anadrol) | Very High | 4–6 weeks maximum |
| Methandrostenolone (Dbol) | High | 4–6 weeks maximum |
| Stanozolol (Winstrol) | High — cholestasis risk | 4–6 weeks maximum |
| Turinabol | Moderate | 6 weeks maximum |
| Oxandrolone (Anavar) | Low to Moderate | 6–8 weeks maximum |
Psychological Side Effects
AAS psychological effects are real but significantly overrepresented in popular media relative to their actual prevalence at typical performance doses.
Aggression and "Roid Rage"
"Roid rage" — explosive, unprovoked aggression — is not universal and is heavily dose-dependent. At typical performance doses (300–500 mg/week testosterone), the majority of users report stable or even improved mood due to supraphysiological testosterone. At very high doses, particularly with highly androgenic compounds like Trenbolone and Halotestin, significant mood instability and aggression are documented. Individual sensitivity varies considerably.
Post-Cycle Depression
The most clinically significant psychological effect — and the most common. As testosterone drops post-cycle and before PCT fully restores natural production, many users experience significant depression, fatigue, anhedonia and motivational collapse. This is hormonally driven — not psychologically. Proper PCT compresses and reduces this window. Users with pre-existing mood disorders are at higher risk for severe post-cycle psychological symptoms.
Dependency
Physical and psychological dependency on AAS is documented in a subset of users. Physical: the body adapts to supraphysiological androgens and the post-cycle hypogonadal period is genuinely unpleasant — creating pressure to restart. Psychological: body image concerns and the desire to maintain physique contribute to continuation despite health concerns. This is a real risk, particularly for younger users and those with underlying body dysmorphia.
Musculoskeletal Risks
AAS produce rapid strength and muscle gains that connective tissue cannot always match. Tendons and ligaments do not have androgen receptors in the same way muscle does — they do not respond to AAS with equivalent adaptation. The result: muscles become dramatically stronger while tendons lag behind — creating injury risk particularly in power movements.
- Tendon rupture: documented risk, particularly Achilles and quadriceps tendons in older users or those with rapid strength increases
- Biceps tendon tears: overrepresented in AAS users — particularly at heavy loads when tendons have not adapted to the muscle strength
- Injury prevention: BPC-157 and TB-500 specifically address this gap — accelerating connective tissue adaptation and repair. Running both during a cycle is the most practical protective measure. See: Best Peptides for Muscle Growth and Recovery
Women — Specific Risks
Women are significantly more sensitive to androgenic effects than men due to dramatically lower baseline androgen levels. Virilisation — the development of male secondary sexual characteristics — can occur rapidly at doses men would consider mild.
Virilisation Effects
- Voice deepening: enlargement of the larynx — the earliest irreversible change. Can begin within weeks of starting an androgenic compound
- Clitoral enlargement (clitoromegaly): DHT-mediated — partially reversible if caught early; may be permanent with prolonged use
- Body and facial hair: androgen-stimulated hair follicle activation — partially reversible
- Skin coarsening and acne
- Menstrual irregularity or cessation
Side Effects by Compound — Quick Reference
| Compound | Estrogenic | Androgenic | Hepatotoxic | Cardiovascular | Suppression |
|---|---|---|---|---|---|
| Testosterone E | High | Moderate | Low | Moderate | Complete |
| Nandrolone (Deca) | Low | Low | Low | Moderate | Very High + Prolactin |
| Trenbolone | None | Very High | Low | High | Extreme + Prolactin |
| Masteron | None | Moderate-High | Low | Moderate | Moderate-High |
| Primobolan | None | Low | Low | Low-Moderate | Low-Moderate |
| Boldenone (EQ) | Low | Low-Moderate | Low | Moderate (haematocrit) | Moderate |
| Dianabol | High | Moderate | High | Moderate-High | Complete |
| Anavar | None | Low | Low-Moderate | Moderate (lipids) | Moderate |
| Winstrol | None | Moderate-High | High | High (HDL) | Moderate-High |
| Superdrol | None | Moderate | Very High | High (lipids) | High |
Reversibility — What Recovers and What Does Not
| Side Effect | Reversibility | Timeline | Notes |
|---|---|---|---|
| Testosterone suppression | Usually reversible | 4–12 weeks with PCT | Permanent hypogonadism possible with prolonged use without PCT |
| Testicular atrophy | Usually reversible | Weeks to months post-PCT | HCG during cycle reduces atrophy severity |
| Sperm count reduction | Usually reversible | 3–12 months post-cycle | Full recovery typical after short cycles with PCT |
| Early gynecomastia | Usually reversible | Weeks if caught early | Established glandular tissue may require surgery |
| Liver enzyme elevation | Reversible | 4–8 weeks post-cycle | Severe hepatic injury less predictably reversible |
| Lipid dysregulation | Usually reversible | 4–12 weeks post-cycle | Cumulative atherosclerotic damage may not reverse |
| Left ventricular hypertrophy | Partially reversible | Months to years | Some degree of LVH persists in ex-users — not fully reversible |
| Acne | Usually reversible | Weeks to months post-cycle | Scarring from severe acne is permanent |
| Hair loss acceleration | Not reversible | N/A | Follicles miniaturised by DHT do not recover |
| Voice deepening (women) | Not reversible | N/A | Laryngeal enlargement is permanent |
| Clitoral enlargement (women) | Partially reversible if caught early | Months | Permanent with prolonged use |
- Windfeld-Mathiasen J. et al. (2025) — review of anabolic-androgenic steroid use among recreational athletes, covering left ventricular hypertrophy (LVH), dyslipidemia, endothelial dysfunction, accelerated atherosclerosis, and long-term cardiovascular risk. Current Opinion in Cardiology. PubMed.
- Windfeld-Mathiasen J. et al. (2024) — review of cardiovascular morbidity associated with anabolic-androgenic steroid use, including hypertension, left ventricular hypertrophy, arrhythmias, thromboembolic disease, and premature cardiovascular events. Ugeskrift for Laeger. PubMed.
- Albano G.D. et al. (2021) — comprehensive literature review of adverse effects associated with anabolic-androgenic steroid use, including cardiovascular, endocrine, hepatic, reproductive, psychiatric, and metabolic complications. Healthcare. PubMed.
- Bond P., Smit D.L., de Ronde W. (2022) — evidence-based review of anabolic-androgenic steroid pharmacology, mechanisms of action, anabolic effects, endocrine suppression, and short- and long-term health risks. Frontiers in Endocrinology. PubMed.
- Leslie S.W., Rahman S., Ganesan K. — Anabolic Steroids: clinical overview of anabolic-androgenic steroid pharmacology, androgen receptor mechanisms, medical use, misuse patterns, monitoring considerations, and adverse effect profile. StatPearls, NIH/NCBI.